T h e Jo u rn a l o f H ea d a ch e a n d P a in V o lu m e 8 · S u p p le m en t 1 · Ju n e 20 0 7 · p p .S 1-S 4 4
The Journal
of Headache
and Pain
Volume 8 Supplement 1 June 20078 · S1
2007
Sp ed iz io n e in a. p. – 45 % – ar t. 2 co m m a 20 /b le gg e 66 2/ 96 – Fi lia le di M ila n o R iv is ta uf fic ia le de lla Eu ro p ea n H ea da ch e Fe de ra ti onOnline edition in SpringerLink – Medicine Online Library http://www.springerlink.com
Indexed in Index Medicus/Medline, EMBASE and Elsevier BIOBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), e-psyche, Derwent Drug File
Printed on acid-free paper
Avai
lable
onlin
e
The
Journal
of Headache
and Pain
The
Journal
of Headache
and Pain
www.sprin gerlink.c omEuropean Headache Federation
in collaboration withLifting The Burden:
The Global Campaign to Reduce the Burden of Headache Worldwide
Aids for management of common
headache disorders in primary care
P R E F A C E1 Aids for management of common headache disorders in primary care T.J. Steiner • P. Martelletti
G U I D E L I N E S
2 European principles of management of common headache disorders in primary care
T.J. Steiner • K. Paemeleire • R. Jensen • D.Valade • L. Savi • M.J.A. Lainez • H.C. Diener • P. Martelletti • E.G.M. Couturier
A P P E N D I X
21 The halt and hart indices T.J. Steiner
25 Information for Patients T.J. Steiner
37 Translation protocols M. Peters
Lifting The Burden:
The Global Campaign to Reduce the Burden of Headache Worldwide
in collaboration with
European Headache Federation
Aids for management of common headache
disorders in primary care
This is a "Springer Open Choice" article. Unrestricted non-commercial use, distribution, and reproduction in any medium is permitted, provided the original author and source are credited.
Aids for management of common headache
disorders in primary care
T.J. Steiner P. Martelletti
T.J. Steiner
Chairman: Global Campaign Committee
Lifting The Burden
P. Martelletti Editor-in-Chief
Journal of Headache and Pain
This work was performed under a collaborative arrangement between World Health Organization and World Headache Alliance, International Headache Society and European Headache Federation
WHO, WHA, IHS, EHF
Medical management of headache disorders, for the vast majority of people affected by them, can and should be carried out in primary care. It does not require specialist skills. Nonetheless, it is recognised that non-specialists throughout Europe may have received limited training in the diagnosis and treat-ment of headache.
This special supplement of Journal of Headache and Painis the out-put of a collaboration between the European Headache Federation (EHF) and Lifting The Burden: the Global Campaign to Reduce the Burden of Headache Worldwide, a programme for the benefit of peo-ple with headache conducted under the auspices of the World Health Organization. It contains a set of management aids designed by vari-ous specialist working groups expressly to assist primary-care physicians in managing a group of very common disorders effectively. We hope for benefits for both patients and physicians. In the first case, there should be better outcomes for the many people with headache who need medical treatment. In the second, physicians are helped to deliver appropriate care more efficiently and more cost-effectively.
Whilst the focus of this publication is Europe, these management aids have been developed to be useful cross-culturally and may suit a wider population.
The European principles of management of common headache disorders in primary care are the essential core of these aids. These are set out in 12 sections, each one more-or-less stand-alone. They are supplemented in Appendices 1 and 2 by a measure of headache burden (the HALT index), intended for pre-treatment assessment of illness severity, an outcome measure (the HART index), which is a guide to follow-up and need for treatment-review, and a series of patient information leaflets developed to improve patients’ understanding of their headache disorders and their management.
EHF and Lifting The Burdenoffer these aids freely available for use without restriction. They will need translating into many languages. Therefore, also included, in Appendix 3, are a set of translation protocols. These have been pre-pared by a working group of Lifting The Burdento ensure that translations as far as possible are unchanged in meaning from the English-language originals.
H.-C. Diener P. Martelletti E.G.M. Couturier
on behalf of the European Headache Federation and
Lifting The Burden: The Global Campaign to Reduce the Burden of Headache Worldwide
Introduction
Headache disorders are amongst the top ten causes of disability in Europe [1]. Three of these (migraine, tension-type headache and medication-overuse headache) are important in primary care because they are common and responsible for almost all headache-related burden. Their management belongs largely in primary care. A fourth headache disorder (cluster headache) is also important because it is severely painful, treatable but often misdiagnosed.
The purpose of these principles is to help primary-care physicians correctly diagnose these few disor-ders, manage them well when they can, recognise warnings of serious headache disorders and refer for
specialist care whenever necessary. These principles are likely to be most useful if read through at least once in their entirety, but are set out in 12 stand-alone management aids in three sections:
Guides to diagnosis (some parts of these will need to be assimilated into routine practice whereas other parts can serve as check lists and aide-mémoires)
1. Headache as a presenting com-plaint
2. Diagnosis of headache
3. Typical features of the common headache disorders
4. Differential diagnosis of the com-mon headache disorders
Guides to management (these are information sources to be referred to
T.J.Steiner
Division of Neuroscience and Mental Health, Imperial College London, London, UK K. Paemeleire
Department of Neurology, Ghent University Hospital. Ghent, Belgium
R. Jensen
Danish Headache Centre, Department of Neurology, University of Copenhagen, Glostrup Hospital, Glostrup, Denmark
D. Valade
Centre d'Urgence des Céphalées, Hôpital Lariboisière, Paris, France
L. Savi
Headache Centre, Department of Neurosciences, University of Turin, Italy
M.J.A. Lainez
Department of Neurology, University Clinic Hospital, Valencia University, Valencia, Spain H.-C. Diener
Department of Neurology, University of Duisberg-Essen, Essen, Germany P. Martelletti
Department of Medical Sciences, Regional Referral Headache Centre, Sant’Andrea Hospital, Sapienza University, Rome, Italy E.G.M. Couturier
Medisch Centrum Boerhaave, Amsterdam, The Netherlands
E.G.M. Couturier (Y) Medisch Centrum Boerhaave, Johannes Vermeerstr 31, 1071 DL Amsterdam, The Netherlands.
once the diagnosis has been made; management aid #6 includes guidance on information to patients)
5. General aspects of headache management 6. Advice to patients
7. Medical management of acute migraine 8. Prophylactic management of migraine
9. Medical management of tension-type headache 10. Medical management of cluster headache 11. Management of medication-overuse headache
Guide to referral (a reference and reminder)
12. Headache management in primary care: when to refer These principles are supplemented by additional manage-ment aids developed by Lifting The Burden:
• the Headache-Attributed Lost Time (HALT) index, a measure of headache burden
• the Headache and Assessment of Response to Treatment (HART) index, a measure of treatment effect and guide to follow-up
• a series of patient information leaflets.
Development process
Stakeholder involvement
The initial development group, a collaboration between the European Headache Federation (EHF) and Lifting The Burden: The Global Campaign to Reduce the Burden of Headache Worldwide, were headache specialists from Belgium, Denmark, France, Germany, Italy, Netherlands, Spain and UK. The pilot group were primary care physicians from the same countries. The consultation group were mem-bers of the National headache societies within the European Headache Federation representing Albania, Austria, Belgium, Belarus, Bulgaria, Croatia, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Portugal, Romania, Russia, Serbia and Montenegro, Slovenia, Spain, Sweden, Switzerland and United Kingdom. Patient representatives and advocates were consulted through the Board of the European Headache Alliance.
Rigour of development
The development process was review of all treatment guide-lines in use in Europe and published or otherwise available in English, and harmonization through selection of whatever recommendations within them carried greatest weight.
Evidence-based recommendations were always preferred to those without explicit supporting evidence. Discordance between recommendations was resolved through direct refer-ence to original evidrefer-ence or, where this was lacking, through consensus of expert opinion.
Clarity and presentation
The aim was to give straightforward and easily-followed guidance to primary-care physicians who were assumed to be non-expert. There was recognition that availability and regu-latory approval of drugs and reimbursement policies varied from country to country. For that reason, different possible options were considered and are set out wherever appropriate, but otherwise the emphasis was on unambiguous advice. Applicability
These principles assume that headache services are developed and adequately resourced in all countries in Europe, even though this is not the case at present. Separate initiatives by EHF and Lifting The Burdenare being undertaken to support better organisation of headache services in all countries in Europe. These recommendations will be monitored by the pilot group and reviewed annually by the development group. Editorial independence
EHF was the sole funding body supporting development of these principles. Members of the development group declared the following possible conflicts of interest:
consultancy agreements with and/or research funding from ACRAF SpA, Addex Pharma, Allergan, Almirall, Alpharma, Astra Zeneca, Bayer Healthcare, Berlin Chemie, Böhringer Ingelheim, Bristol-Myers Squibb, CoLucid, Eli Lilly, Glaxo-SmithKline, Grünenthal, Helsinn Healthcare, Hoffmann La Roche, Janssen-Cilag, Johnson & Johnson, Lusofarmaco, Menarini, Merck Sharpe and Dohme, 3M Medica, Novartis, Pfizer, Pierre Fabré, Solvay Pharma, SanofiAventis, Sanofi-Synthélabo, Schaper and Brümmer, Weber & Weber. These principles make no recommendations that favour one proprietary medication over another with similar effects.
References
1. Stovner LJ, Hagen K, Jensen R et al (2007) The global burden of headache: a documentation of headache prevalence and dis-ability worldwide. Cephalalgia 27:193–210
1. Headache as a presenting complaint
Most people have occasional headache, and regard it as normal. Headache becomes a problem at some time in the lives of about 40% of people in Europe. Four headache disorders are common in primary care (Table). All have a neurobiological basis. They are disabling and impair quality of life.
One patient may have more than one of these disorders con-comitantly.
There are a large number of other secondary headache dis-orders. Some of these are serious, and they must be recog-nized (see Management aid #4. Differential diagnosis of the common headache disorders), but overall they account for <1% of patients presenting with headache.
Table The common headache disorders in primary care
Migraine usually episodic, occurring in 12-16% of the general population, in women more than men in a ratio of 3:1
Tension-type usually episodic, affecting >80% of people from time to time; in at least 10% it recurs frequently, and in 2-3% of adults headache and some children it is chronic, occurring on more days than not
Cluster intense and frequently recurring but short-lasting headache attacks, affecting up to 3 in 1,000 men headache and up to 1 in 2,000 women
Medication- a chronic daily headache syndrome occurring in up to 3% of adults, 5 women to each man, and 1% of
overuse children and adolescents; this is a secondary headache, but it occurs only as a complication of a pre-existing headache headache disorder, usually migraine or tension-type headache
2. Diagnosis of headache
Taking a diagnostic history
The history is all-important in the diagnosis of the primary headache disorders and of medication-overuse headache (Table). There are no useful diagnostic tests. The history should elicit any warning features of a serious secondary headache disorder.
Warning features in the history
Any new headache in an individual patient, or a significant change in headache characteristics, should be treated with caution.
Specific warning features are:
• thunderclap headache (intense headache with “explosive” or abrupt onset) (suggests subarachnoid haemorrhage) • headache with atypical aura (duration >1 hour, or
includ-ing motor weakness) (may be symptoms of TIA or stroke) • aura without headache in the absence of a prior history of migraine with aura (may be a symptom of TIA or stroke) • aura occurring for the first time in a patient during use of
combined oral contraceptives (indicates risk of stroke) • new headache in a patient older than 50 years (may be a
symptom of temporal arteritis or intracranial tumour), or in a pre-pubertal child (requires specialist referral and diagnosis) • progressive headache, worsening over weeks or longer
(may indicate intracranial space-occupying lesion) • headache aggravated by postures or manoeuvres that raise
intracranial pressure (may indicate intracranial tumour) • new headache in a patient with a history of cancer, HIV
infection or immunodeficiency (likely to be secondary headache).
Diagnostic diary
Once serious causes have been ruled out, a headache diary kept over a few weeks clarifies the pattern of headaches and associated symptoms as well as medication use or overuse.
Physical examination of headache patients
Migraine, tension-type headache, cluster headache and med-ication-overuse headache are diagnosed solely on history. Signs are present in cluster headache patients when seen dur-ing attacks. Physical examination is mandatory when the his-tory is suggestive of secondary headache.
Warning features on examination • pyrexia associated with headache
• focal neurological signs associated with headache Investigation of headache patients
Investigations, including neuroimaging, are indicated when the history or examination suggest headache may be sec-ondary to another condition.
Table Questions to ask in the history
How many different headaches types does the patient have?A separate history is needed for each.
Time questions • Why consulting now? • How recent in onset?
• How frequent, and what temporal pattern (episodic or daily and/or unremitting)? • How long lasting?
Character questions• Intensity of pain?
• Nature and quality of pain? • Site and spread of pain? • Associated symptoms?
Cause questions • Predisposing and/or trigger factors? • Aggravating and/or relieving factors? • Family history of similar headache?
Response questions • What does the patient do during the headache?
• How much is activity (function) limited or prevented?
• What medication has been and is used, in what manner and with what effect? State of health • Completely well, or residual or persisting between attacks symptoms?
• Concerns, anxieties, fears about recurrent attacks and/or their cause?
in conjunction with
Lifting The Burden
European principles of management
of common headache disorders in
3. Typical features of the common headache disorders
Migraine
Migraine occurs in two principal subtypes, migraine without aura and migraine with aura. One patient may have both. Migraine without aura
Adultswith this disorder typically describe:
• recurrent episodic moderate or severe headaches which: - are often unilateral and/or pulsating
- last 4 hours to 3 days
- are often associated with nausea and/or vomiting - are aggravated by routine physical activity
• during which they limit activity and prefer dark and quiet • with freedom from symptoms between attacks.
In children:
• attacks may be shorter-lasting
• headache is more commonly bilateral and less usually pul-sating
• gastrointestinal disturbance is more prominent. Migraine with aura
Migraine with aura affects one third of people with migraine and accounts for 10% of migraine attacks overall. It is char-acterised by aura preceding headache, consisting of one or more neurological symptoms that develop gradually over >5 minutes and resolve within 60 minutes:
• hemianopic visual disturbances, or a spreading scintillating scotoma (patients may draw a jagged crescent if asked) • and/or unilateral paraesthesiae of hand, arm and/or face • and/or (rarely) dysphasia.
Otherwise similar to migraine without aura.
Typical aura without headache may occur in patients with a past history of migraine with aura.
Tension-type headache
This disorder occurs in three subtypes. Only two of these are
medically important: frequent episodic tension-type headache and chronic tension-type headache.
Frequent episodic tension-type headache:
• occurs in attack-like episodes, at least once a month, last-ing hours to a few days
• can be unilateral but is more often generalised
• is typically described as pressure or tightness like a vice or tight band around the head, or is felt in the neck
• lacks the associated symptom complex of migraine. Chronic tension-type headache
• occurs by definition on ≥15 days a month for >3 months and may be daily and unremitting
• otherwise is similar to frequent episodic tension-type headache.
Cluster headache
This highly recognisable condition occurs in two subtypes, episodic cluster headache and chronic cluster headache. Episodic cluster headache occurs in bouts (clusters), typical-ly of 6-12 weeks’ duration, once a year or two years, and then remits until the next cluster.
Chronic cluster headache, which persists without remissions, is less common. It may develop from and/or revert to episod-ic cluster headache.
Cluster headache: • mostly affects men
• manifests as strictly unilateral, excruciating pain around the eye
• recurs frequently, typically once or more daily, commonly at night
• is short-lasting, for 15-180 minutes (typically 30-60 min-utes)
• has highly characteristic and strictly ipsilateral autonomic features including any of:
- red and watering eye - running or blocked nostril - ptosis
• causes marked agitation (the patient, unable to stay in bed, paces the room, even going outdoors).
Summary of features distinguishing the common headache disorders (NB: two or more may occur concomitantly)
Migraine Tension type headache (TTH) Cluster headache (CH)
Temporal pattern recurrent attack- Episodic TTH: Episodic CH:
like episodes, lasting recurrent attack-like episodes short-lasting attacks (15-180 minutes)
4 hours to 3 days; lasting hours to a few days; recurring frequently (typically ≥1 daily)
in bouts of 6-12 weeks’ duration once
frequency often 1-14 days affected per month; a year or two years, and then remitting
1-2/month but variable
from 1/year to 2/week; freedom from symptoms Chronic CH:
between attacks similar, but without remissions
freedom from symptoms between bouts
between attacks Chronic TTH:
≥15 days affected per month
(often daily and unremitting)
Typical headache often unilateral can be unilateral but more often strictly unilateral, around the eye characteristics and/or pulsating generalised; may be felt
in the neck;
typically described as pressure or tightness
Headache intensity typically moderate to severe typically mild to moderate very severe
Associated often nausea and/or vomiting; none strictly ipsilateral autonomic features:
symptoms any of red and watering eye, running
often photo- and/or phonophobia (mild nausea, but not vomiting, or blocked nostril, ptosis
may accompany chronic TTH)
Reactive behaviour avoidance of physical activity none specific marked agitation (maybe bed rest);
preference for dark and quiet
Medication-overuse headache
Medication-overuse headache, a chronic daily headache syn-drome, is an aggravation of a prior headache (usually migraine or tension-type headache) by chronic overuse of medication taken to treat headache or other pain.
All acute headache medications may have this effect. Frequency, regularity and duration of intake are important determinants of risk.
A history can be elicited of increasingly frequent headache episodes, with increasing medication use, over months to many years.
Medication-overuse headache • is associated with:
- regular use of simple analgesics on ≥15 days a month
and/or
- regular use of opioids, ergots or triptans, or any combina-tion of these, on ≥10 days a month
• occurs daily or near-daily
• is present – and often at its worst – on awakening in the morning
• is initially aggravated by attempts to withdraw the medication. Diagnosis of medication-overuse headache is confirmed if symptoms improve within 2 months after overused medication is withdrawn.
4. Differential diagnosis of the common headache disorders
Each of the primary headaches is in the differential diagno-sis of each of the others. Medication-overuse headache is in the differential diagnosis of migraine and tension-type headache.
Otherwise, the differential diagnosis includes a small num-ber of serious secondary headaches that are important to recognise.
Warning features in the history or on examination
• headache that is new or unexpected in an individual patient, or develops new features
• thunderclap headache (intense headache with abrupt or “explosive” onset) (may be indicative of subarachnoid haemorrhage)
• headache with atypical aura (duration >1 hour, or includ-ing motor weakness) (may be symptoms of TIA or stroke)
• aura without headache in the absence of a prior history of migraine with aura (may be a symptom of TIA or stroke) • aura occurring for the first time in a patient during use of
combined oral contraceptives (indicates risk of stroke) • new headache in a patient older than 50 years (may be a
symptom of temporal arteritis or intracranial tumour) or in a pre-pubertal child (requires specialist referral for diagno-sis)
• progressive headache, worsening over weeks or longer (may indicate intracranial space-occupying lesion) • headache associated with or aggravated by postural change
or other manoeuvres that raise intracranial pressure (may indicate intracranial tumour)
• new headache in a patient with a history of cancer, HIV infection or immunodeficiency (likely to be secondary headache)
• otherwise unexplained pyrexia associated with headache (may indicate meningitis)
• focal neurological signs associated with headache (sug-gests secondary headache)
5. General aspects of headache management
The following principles are generally important for all headache disorders managed in primary care.
Acknowledging impact
• Recurrent disabling headache is a burden on the person with it, and has an impact on other people. These include the family, work colleagues and employer.
• Recurrent disabling headache may lead to lifestyle compro-mise, either in response to attacks or in a bid to avoid them. In this way, episodic headache can have continuous impact. The HALT index developed by Lifting The Burden(Appendix 1) is an instrument for assessing burden in terms of lost time. Realistic aims of management
• Headache disorders cannot be cured but can be effectively managed in most cases.
• They usually remit in old age. Reassurance and explanation
• Many people with recurrent headache wrongly fear underly-ing disease. Appropriate reassurance should never be omitted. • Explanation is a crucial element of preventative manage-ment in patients with migraine or frequent episodic ten-sion-type headache who are at risk of escalating medica-tion consumpmedica-tion.
A series of patient information leaflets developed by Lifting The Burden(Appendix 2) are currently available in Danish, Dutch, English, French, German, Italian, Portuguese and Spanish. They provide basic explanations of migraine, ten-sion-type headache, cluster headache and medication-overuse headache and their treatment.
Causes and triggers
• Whilst patients want to know the cause of their headache,
this may not be possible. Both genetic and environmental factors contribute to processes that are not well under-stood.
• Many patients seek help in identifying triggers. The importance of trigger factors in migraine is over-empha-sised. When they are relevant to individual patients, they are usually self-evident. Triggers may be less readily identified when they are cumulative in their effect, jointly contributing to a “threshold” above which attacks are ini-tiated. Even when identified, triggers are not always avoidable.
• Contrary to popular belief, there is no “migraine diet”. The only dietary triggers with evidential support are alcohol and monosodium glutamate.
Follow-up
Every patient to whom treatment is offered, or whose treat-ment is changed, requires follow-up in order to ensure that optimum treatment has been established.
The use of an outcome measure is recommended. The HART index (Appendix 1) is expressly to guide follow-up in pri-mary care.
Persistent management failure is an indication for specialist referral.
Diaries and calendars
Diaries are recommended for:
• recording symptoms and temporal patterns that contribute to correct diagnosis
• recording medication use and overuse
• revealing associations with the menstrual cycle and other triggers.
Calendars are recommended for:
• encouraging compliance with prophylactic medication • recording treatment effect
• monitoring acute medication use or overuse during follow-up • charting outcomes.
in conjunction with
Lifting The Burden
European principles of management
of common headache disorders in
6. Advice to patients
Patients with headache disorders commonly request infor-mation. Many find or have found misleading information on the internet.
Non-drug treatments
Patients enquiring about the following may be given this advice:
• Biofeedback and relaxation therapies can be helpful, and are potentially useful options when drug treatments must be avoided. Their basis requires that only skilled therapists should provide them, but very few skilled thera-pists are available in most countries.
• Physiotherapyhas proven benefits in some patients with tension-type headache. It requires skilled and individu-alised therapy which is not widely available in many coun-tries.
• Acupuncturebenefits some people with migraine or ten-sion-type headache although large clinical trials have failed to distinguish between acupuncture and sham proce-dures. It requires skilled and individualised therapy. • Transcutaneous electrical nerve stimulation (TENS)
may help in chronic pain but is of unproven value in treat-ing headache disorders.
• Herbalsare mostly not recommended. Butterbur has some efficacy according to clinical trials and is approved for use in some countries but preparations on sale elsewhere are variable in content and have uncertain toxicity. Feverfew preparations on sale everywhere are highly variable in content and their toxicity is not well understood.
• Homoeopathyis of unproven value. There is no arguable case for over-the-counter sales of homoeopathic remedies. • Reflexologyhas no scientific basis.
• Devices: many are on the market, some costly and pro-moted with unsupportable claims of efficacy. “Testimonials” can be attributed to placebo effect and should be disregarded.
• Cold packsapplied to the head and/or neck are found by some people to relieve pain or discomfort.
• Dental treatment, including splints and bite-raising appli-ances, is of unproven value in treating headache and should be discouraged for this purpose.
• Spectaclesshould be professionally prescribed and worn when needed, but refractive errors are rarely a cause of troublesome headache.
• Closure of patent foramen ovale (PFO): there is insuffi-cient evidence to support the hypothesis that migraine fre-quency is improved by PFO closure, a procedure which carries a small but relevant risk of serious adverse events including stroke, pericardial tamponade, atrial fibrillation and death. Further prospective trials are underway, and PFO closure should not be undertaken for migraine pro-phylaxis outside these trials.
• Other surgical procedures on the face or neckproduce no benefit and are potentially harmful.
Hormonal contraception and HRT
Headache is often a side-effect of combined oral contracep-tives (COCs) and many women report onset or aggravation of migraine after starting them.
The following advice on hormonal contraception may be given to patients with migraine:
• both migraine with aura and the ethinyloestradiol compo-nent of COCs are independent risk factors for stroke in young women
• alternatives to COCs are recommended for women with migraine with aura and additional risk factors for stroke (including smoking)
• progestogen-only contraception is acceptable with any subtype of migraine.
Hormone replacement therapy (HRT) is not contraindicated in migraine; decisions about commencing or continuing HRT should be made according to generally applicable crite-ria.
Resources for the patient
Lifting The Burden has produced a series of patient informa-tion leaflets on the common headache disorders and their treatment and one on female hormones and headache (Appendix 2). These are currently available in Danish, Dutch, English, French, German, Italian, Portuguese and Spanish.
World Headache Alliance
WHA is a charitable umbrella organisation. Its website car-ries much information for people with headache, and links to many other helpful sites including those of its member organisations in 26 countries.
7. Medical management of acute migraine
All adults with migraine should have access to acute med-ication.
Children with short-lasting attacks may respond well to bed-rest without medical treatment.
In adults and children, regular use of acute medication at high frequency (on >2 days/week) risks the development of medication-overuse headache.
Drug intervention
All patients should climb a treatment ladder (stepped man-agement), usually treating three attacks at each step before proceeding to the next. This strategy, if followed correctly, reliably achieves the most effective and cost-effective indi-vidualised care.
Step one: symptomatic therapy • simple analgesic
• plus, if needed, an antiemetic.
Local guidelines may recommend trying more than one analgesic in step one before proceeding to step two. Paracetamol has limited evidence of efficacy and is not first-line treatment.
Principles of step one
• use soluble analgesics, or mouth-dispersible formulations • take early in the attack, in adequate dosage
• a prokinetic antiemetic inhibits gastric stasis, an early fea-ture of migraine that impairs bioavailability of oral med-ication
• rectal administration may be preferable in the presence of vomiting:
- analgesic suppositories (any of diclofenac 100 mg, ibuprofen 400 mg, ketoprofen 100-200 mg or naproxen 500-1000 mg)
- if needed, antiemetic suppositories (either domperidone 30 mg or metoclopramide 20 mg).
Step one for children (when needed)
• analgesic: ibuprofen 200-400 mg according to age and weight
• antiemetic: domperidone 10-20 mg according to age and weight.
Step two: specific therapy
Analgesics Antiemetics
acetylsalicylic acid 900-1000 mg domperidone 20 mg or
(adults only) or metoclopramide 10 mg
ibuprofen 400-800 mg or
diclofenac 50-100 mg or
ketoprofen 100 mg or
naproxen 500-1000 mg
or(where these are
contraindicated) paracetamol 1000 mg
Specific anti-migraine drugs, formulations and doses available for step two
(availability varies from country to country)
almotriptan tablets 12.5 mg
eletriptan tablets 20 mg and 40 mg (80 mg may be
effective when 40 mg is not)
frovatriptan tablets 2.5 mg
naratriptan tablets 2.5 mg
rizatriptan tablets 10 mg (and 5 mg, to be used when
propranolol is being taken concomitantly); mouth-dispersible wafers 10 mg
sumatriptan tablets and rapidly dissolving tablets 50 mg
and 100 mg; suppositories 25 mg; nasal spray 10 mg (licensed for adolescents) and 20 mg; subcutaneous injection 6 mg
zolmitriptan tablets 2.5 mg and 5 mg; mouth-dispersible
tablets 2.5 mg and 5 mg; nasal spray 5 mg ergotamine tartrate tablets 1 mg and 2 mg; suppositories 2 mg
Principles of step two
• where available, and unless contra-indicated, triptans should be offered to all patients failing step one
• ergotamine has very low and unpredictable bioavailabili-ty, which impairs its efficacy, and complex pharmacology and long duration of action, which lead to poor tolerabili-ty
• triptans should not be used regularly on more than 10 days per month to avoid the risk of medication-overuse headache
• triptans differ slightly, but there are large and unpre-dictable individual variations in response to them; one may work where another has not; patients should try sev-eral, in different formulations, and choose between them • the initial dose of all oral triptans (except, in some cases,
eletriptan) is one tablet
• a second dose for non-response is not recommended by most triptan manufacturers but, taken not less than 2 hours after the first, may be effective in some cases
• triptans are more effective when taken whilst headache is still mild (this instruction should be given only to patients who can reliably distinguish migraine from tension-type headache)
• when nausea is present, domperidone 20 mg or metoclo-pramide 10 mg may be added
• when vomiting is present, sumatriptan suppositories, zolmitriptan nasal spray (absorbed through the nasal mucosa) or sumatriptan subcutaneous injection may be preferred
• when all other triptans are ineffective, sumatriptan by sub-cutaneous injection 6 mg should be considered
• triptans are associated with return of symptoms within 48 hours (relapse) in up to 40% of patients who have initial-ly responded.
Treatment of relapse
• a second dose of a triptan is usually effective
• this second dose may lead to further relapse (when this happens repeatedly, the triptan should be changed) • NSAIDs may be an effective alternative.
Avoidance of relapse
• limited evidence suggests that either of the following may prevent some relapses:
- concomitant use of a triptan and an NSAID
- use of a triptan followed by an NSAID 6-12 hours later. Contraindications to step two
Pregnancy is a general contraindication to ergotamine and to all triptans. There are specific precautions attached to some triptans (see pharmacopoeia).
All triptans and ergots should be avoided by people with: • uncontrolled hypertension
• coronary heart disease, cerebrovascular disease and periph-eral vascular disease
• multiple risk factors for coronary or cerebrovascular disease. Step two for children
No specific anti-migraine drug has been shown to have effica-cy in children (under 12 years old). Failure of step one is an indication for specialist referral.
Follow-up
Every patient to whom treatment is offered, or whose treat-ment is changed, requires follow-up in order to ensure that optimum treatment has been established. Use of a calendar is recommended to monitor acute medication use or overuse and record treatment effect. The use of an outcome measure is rec-ommended. The HART index (Appendix 1) is expressly to guide follow-up in primary care. Failure of acute therapy may be an indication for prophylaxis (see Management aid #8. Prophylactic management of migraine).
Information for patients
Lifting The Burden has produced an information leaflet on migraine and its treatment (Appendix 2). This is currently available in Danish, Dutch, English, French, German, Italian, Portuguese and Spanish.
8. Prophylactic management of migraine
Any patient whose quality of life is impaired by migraine, whether adult or child, may require prophylaxis in addition to acute medication.
Indications for prophylaxis
Prophylactic therapy may be addedwhen:
• attacks cause disability on two or more days per month, and
• optimised acute therapy does not prevent this, and • the patient is willing to take daily medication. Other indications for prophylaxis are:
• risk of over-frequent use of acute therapy, even when it is effective (but prophylactic drugs are inappropriate for medication-overuse headache)
• for children with frequent absences from school. Effective drugs
All of these drugs have contra-indications and side-effects (refer to pharmacopoeia).
Principles of prophylaxis
• A calendar should be kept by every patient on prophylax-is to assess efficacy and promote compliance.
• Poor compliance is a major factor impairing efficacy of migraine prophylactics; once-daily dosing is associated with better compliance.
• The dose of any drug should start low in the suggested range and be increased in the absence of troublesome side-effects. • Drugs that appear ineffective should not be discontinued
too soon; 2-3 months may be the minimum to achieve and observe efficacy.
• Failure of one drug does not predict failure of others in a different class.
• Tapered withdrawal may be considered after 6 months of good control, and should be considered no later than after 1 year.
• Amitriptyline may be preferred when migraine coexists with tension-type headache, depression or sleep disturbance. • Propranolol has best evidence of safety during pregnancy. Prophylaxis in children
• Beta-blockers (dosage adjusted according to body weight) or flunarizine (dosage adjusted according to age) may be tried. Follow-up
Every patient to whom prophylactic treatment is offered, or whose treatment is changed, requires follow-up in order to ensure that optimum treatment has been established. Use of a calendar is recommended to encourage compliance with prophylactic medication and record treatment effect. The use of an outcome measure is recommended. The HART index (Appendix 1) is expressly to guide follow-up in primary care.
If prophylaxis fails
• failure may be due to subtherapeutic dosage or insufficient duration of treatment
• review the diagnosis
Prophylactic drugs with good evidence of efficacy (availability and regulatory approval vary from country
to country; use of drugs off-licence rests on individual clinical responsibility)
beta-adrenergic atenolol 25-100 mg bd or
blockers without bisoprolol 5-10 mg od or
partial agonism metoprolol 50-100 mg bd or
propranolol LA 80 mg od-160 mg bd
topiramate 25 mg od-50 mg bd
flunarizine 5-10 mg od
sodium valproate 600-1500 mg daily
• review compliance
• review other medication, especially for overuse
• when prophylaxis still fails to have clear benefit, discon-tinue it
• if all options fail, specialist referral is indicated. Information for patients
Lifting The Burdenhas produced an information leaflet on migraine and its treatment (Appendix 2). This is currently available in Danish, Dutch, English, French, German, Italian, Portuguese and Spanish.
Hormonal contraception and HRT
Many women report onset or aggravation of migraine after starting combined oral contraceptives (COCs). Others report improvement of pre-existing migraine.
The following advice on hormonal contraception may be given:
• both migraine with aura and the ethinyloestradiol compo-nent of COCs are independent risk factors for stroke in young women
• alternatives to COCs are recommended for women with migraine with aura and additional risk factors for stroke (including smoking)
• progestogen-only contraception is acceptable with any subtype of migraine.
Hormone replacement therapy (HRT) is not contraindicated in migraine. Decisions about commencing or continuing HRT should be made according to generally applicable cri-teria.
Lifting The Burden has produced an information leaflet on female hormones and headache (Appendix 2).
Botulinum toxin (Botox)
Patients may ask about this treatment.
There is insufficient evidence to support the efficacy of Botox in migraine prevention. This treatment is not current-ly recommended.
Patent foramen ovale (PFO) and migraine Patients may ask about this treatment.
There is insufficient evidence to support the hypothesis that migraine frequency is improved by PFO closure. This pro-cedure carries a small but relevant risk of serious adverse events including stroke, pericardial tamponade, atrial fibril-lation and death. Further prospective trials are underway. PFO closure should not be undertaken for migraine prophy-laxis outside these trials.
9. Medical management of tension-type headache
Drug therapy has limited scope in tension-type headache but, within these limitations, is effective in many patients. Eitheracute medication or prophylaxis may be indicated. Acute medication should be used with care when headache is frequent because of the risk of medication overuse. Acute intervention
• Symptomatic treatment with over-the-counter analgesics is appropriate for episodic tension-type headache occur-ring on ≤2 days per week:
- acetylsalicylic acid 600-1000 mg (adults only) - ibuprofen 400-800 mg
- paracetamol 1000 mg is less effective.
• Episodic tension-type headache on >2 days per week is an indication for prophylaxis in place of, rather than in addition to, acute intervention.
• These treatments are unlikely to be effective in chronic tension-type headache and put the patient at risk of med-ication-overuse headache.
Principles of acute intervention
• Opioids should be avoided; in particular: - codeine and dihydrocodeine
- dextropropoxyphene
- combination analgesics containing any of these. • Barbiturates have no place in the treatment of
tension-type headache.
• As the frequency of headaches increases, so does the risk of medication overuse.
Prophylaxis
• Amitriptyline, 10-100 mg at night, is the drug of choice for frequent episodic or chronic tension-type headache. • Nortriptyline causes fewer anticholinergic side-effects
but has less good evidence of efficacy (amitriptyline can be replaced by nortriptyline at the same dose).
Principles of prophylaxis
• Intolerance is reduced by starting at a low dose (10 mg) and incrementing by 10-25 mg each 1-2 weeks.
• A calendar should be kept to assess efficacy and promote compliance.
• Prophylaxis that appears ineffective should not be dis-continued too soon; 2-3 months may be the minimum to achieve and observe efficacy.
• Tapered withdrawal may be considered after 6 months of good control, but prolonged treatment is sometimes indicated. Follow-up
Every patient to whom treatment is offered, or whose treat-ment is changed, requires follow-up in order to ensure that optimum treatment has been established. Use of a calendar is recommended to monitor acute medication use or overuse, or to encourage compliance with prophylactic medication, and to record treatment effect. The use of an outcome measure is recommended. The HART index (Appendix 1) is expressly to guide follow-up in primary care.
If prophylaxis fails
• failure may be due to subtherapeutic dosage or insuffi-cient duration of treatment
• review the diagnosis
• review compliance (patients who are not informed that they are receiving medication often used as an antide-pressant, and told why, may default when they find out) • review other medication, especially for overuse
• when prophylaxis still fails to have clear benefit, discon-tinue it
• if all options fail, specialist referral is indicated. Pain management
Despite best efforts, chronic tension-type headache is often refractory to medical treatment.
Patients in this situation require a pain management pro-gramme with emphasis on psychological approaches.
Information for patients
Lifting The Burdenhas produced an information leaflet on tension-type headache and its treatment (Appendix 2). This is currently available in Danish, Dutch, English, French, German, Italian, Portuguese and Spanish.
Botulinum toxin (Botox)
Patients may ask about this treatment.
There is insufficient evidence to support the efficacy of Botox in tension-type headache. This treatment is not cur-rently recommended.
10. Medical management of cluster headache
Cluster headache management is usually better left to experi-enced specialists who see this disorder frequently. Recognition in primary care is crucial to ensure prompt referral. The objec-tive in both episodic and chronic cluster headache is total attack suppression. This is not always achievable. Both acute medication and prophylaxis have a role in management, but preventative drugs are the mainstay of treatment in most cases. Acute therapies
• Sumatriptan 6 mg subcutaneously is the only proven highly-effective acute treatment, but cannot be recom-mended for use more than twice a day.
• Oxygen 100% at ≥7 l/min for up to 15 min (requires a
non-rebreathing mask and regulator) helps some people and may be used as frequently as needed.
• Analgesics, including opioids, have no place in treating cluster headache.
Prophylaxis Principles
• drugs in the table are used by specialists, balancing effi-cacy against toxicity
• prophylaxis of episodic cluster headache should begin as early as possible after the start of a new cluster bout and (except for prednisolone, which is used in short courses only) should be discontinued by tapering 2 weeks after full remission
• for chronic cluster headache, treatments may need to be continued long-term
• failure of one drug does not predict failure of others • combinations may be tried, but the potential for toxicity
is obviously high.
Follow-up
Every patient with active cluster headache requires frequent follow-up both to ensure that optimum treatment is main-tained and to monitor for treatment toxicity.
Information for patients
Lifting The Burdenhas produced an information leaflet on cluster headache and its treatment (Appendix 2). This is currently available in Danish, Dutch, English, French, German, Italian, Portuguese and Spanish.
Drugs used by specialists in cluster headache prophylaxis (all are potentially toxic: refer to pharmacopoeia)
verapamil 240-960 mg daily ECG monitoring is advised
prednisolone 60-80 mg od may need repeating because
for 2-4 days, discontinued of relapse during dose reduction
by dose reduction over 2-3 weeks
lithium carbonate levels must be monitored
600-1600 mg daily
ergotamine tartrate usually omitted every 7th day
2-4 mg daily per rectum may not be used concomitantly
with sumatriptan
usage interrupted for at least 1 month in every 6 months methysergide 1-2 mg tds
not recommended to be used concomitantly with sumatriptan
11. Management of medication-overuse headache
Medication-overuse headache is an aggravation of a prior primary headache by chronic overuse of medication taken to treat it.
Once this condition has developed, early intervention is important. The long-term prognosis depends on the dura-tion of medicadura-tion overuse.
Management
• Prevention, through education, is better than cure. • The only effective treatment of established
medication-overuse headache is withdrawal of the suspected medica-tion(s).
Objectives
There are four separate objectives in the complete manage-ment of MOH, and all are important:
• the first is to achieve withdrawal from the overused med-ication
• the second, which should follow, is recovery from MOH • the third is to review and reassess the underlying primary headache disorder (migraine or tension-type headache) • the fourth is to prevent relapse.
Principles
• clear explanation that the “treatment” a patient is taking for headache is actually the causeof it is vital to success • patients may be reassured that the outcome of
withdraw-al is usuwithdraw-ally good
• with forewarning, withdrawal is most successfully done abruptly; admission to hospital is rarely necessary. • withdrawal leads initially to worsening headache, so
should be planned to avoid unnecessary lifestyle disrup-tion (1-2 weeks’ sick leave may be needed)
• after 1-2 weeks, usually, headache shows signs of improvement
• recovery continues slowly for weeks to months. Follow-up
• every patient withdrawing from medication requires fol-low-up in order to provide support and observe outcome • first review is advised after 2-3 weeks to ensure
with-drawal has been achieved
• use of a calendar is strongly recommended to record symptoms and medication use during withdrawal, and to record changing headache pattern
• most patients revert to their original headache type (migraine or tension-type headache) within 2 months; this will need review and appropriate management • further follow-up is important to avoid relapse, and most
patients require extended support: the relapse rate is around 40% within five years.
Re-introducing withdrawn medication
• withdrawn medications should subsequently be avoided as far as is possible
• when needed, they may be cautiously reintroduced after 2 months
• frequency of use should never exceed 2 days/week on a regular basis.
Information for patients
Lifting The Burdenhas produced an information leaflet on medication-overuse headache and its management (Appendix 2). This is currently available in Danish, Dutch, English, French, German, Italian, Portuguese and Spanish.
in conjunction with
Lifting The Burden
European principles of management
of common headache disorders in
12. Headache management in primary care: when to refer
Most primary headaches, and medication-overuse headache, can best be managed in primary care.
Reasons for specialist referral:
• diagnostic uncertainty after due enquiry
• diagnosis of cluster headache (most cases are best man-aged by specialists)
• suspicion of serious secondary headache, or cases where investigation may be necessary to exclude serious pathol-ogy (referral may need to be immediate):
- any headache that is new or unexpected in an individual patient, but especially:
. newly-occurring thunderclap headache (intense headache with abrupt or “explosive” onset) . new headache in a patient older than 50 years . new headache in a pre-pubertal child
. new headache in a patient with a history of cancer, HIV infection or immunodeficiency
- unusual migraine aura, especially: . aura with duration >1 hour . aura featuring motor weakness
. aura without headache in the absence of a prior history of migraine with aura
. aura first occurring with use of combined oral contraceptives
- progressively worsening headache over weeks or longer - headache associated with postural change indicative of
high or low intracranial pressure
- headache associated with unexplained fever
- headache associated with unexplained physical signs • persistent management failure
• comorbid disorders requiring specialist management • presence of risk factors for coronary heart disease may
Introduction
Assessment of a headache disorder as a prelude to planning best manage-ment requires more than diagnosis: there should be some measure or esti-mation of the impact of the disorder on the patient’s life and lifestyle. There are many ways in which recur-rent or persistent headache can dam-age life. Finding a simple measure that summarises these in a single index, and which is equally applicable for all of the common headache disor-ders, is quite a challenge. The MIDAS instrument developed by Stewart and Lipton [1] has proved extremely use-ful. The concept behind it is simple enough: it estimates active time lost through the disabling effect of headache, and the result is expressed by a number with intuitively meaning-ful units (hours).
The HALT index is a direct and close derivative of MIDAS. It was devel-oped by Lifting The Burdento use wording that is more easily translated. Whenever treatment is started, or changed, follow-up ensures that opti-mum treatment has been established or recognizes that it has not and iden-tifies any further change to treatment that may be needed.
It is not always easy to know whether or not the outcome that has been achieved by an individual patient is the best that the patient can reasonably expect. For the non-specialist, one question that sometimes arises is: “What further effort, in hope of a bet-ter outcome, is justified?” A second question, which follows if it is thought
that more should be done, may be “What is it that needs changing?” An international working group* of Lifting The Burdenis developing the Headache Under-Response to
Treatment (HURT) index, an outcome measure that is designed to aid man-agement by suggesting answers to these two questions. This index will be published later, elsewhere. The instrument that is included here is its forerunner, pending validation. To dis-tinguish between them, it is referred to as the Headache and Assessment of Response to Treatment (HART) index.
*Lifting The Burden Working group on Outcome Measures:
R. Lipton (chairman) (USA), M. Al Jumah (Saudi Arabia), B. Eggleston (Australia), M. Fontebasso (UK), L. Gardella (Argentina), R. Jensen (Denmark), H. Kettinen (Finland), M.J.A. Láinez (Spain), F. Mennini (Italy), M. Peters (Netherlands/UK), K. Ravishankar (India), F. Sakai (Japan), N. Sharma (India), TJ. Steiner (UK), W. Stewart (USA), A.D. Tehindrazana-rivelo (Madagascar/France), D. Valade (France), M. Von Korff (USA), S.Y. Yu (PR China)
Reference
1. Stewart WF, Lipton RB, Kolodner K et al (2000) Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine suf-ferers. Pain 88:41–52
The HALT and HART indices
T.J. Steiner
T.J. Steiner
Chairman: Global Campaign
HALT Index* (Headache-Attributed Lost Time)
Your doctor or nurse may give you this short questionnaire before starting treatment.
Please answer the five simple questions. This will help your doctor or nurse understand how
much your headaches are affecting your life, and guide your medical treatment.
1
On how many
days
in the
last three months
could you
not go
to work or school because of your headaches?
2
On how many
days
in the
last three months
could you do
less than half
your usual amount in your job or schoolwork
because of your headaches? (Do not include days you counted
in question 1 where you missed work or school)
3
On how many
days
in the
last three months
could you not do
any household work because of your headaches?
4
On how many
days
in the
last three months
could you do
less
than half
your usual amount of household work because
of your headaches? (Do not include days you counted
in question 3 where you did not do household work.)
5
On how many
days
in the
last three months
did you
miss
family, social or leisure activities because of your headaches?
Grading(I-IV indicate, in order, increasing need for medical care; either III or IV indicates high need)
0-5 Minimal or infrequent impact Grade I
6-10 Mild or infrequent impact Grade II
11-20 Moderate impact Grade III
20+ Severe impact Grade IV
TOTAL
* HALT is closely based on the first five questions of MIDAS, developed by R.B. Lipton and W.F. Stewart
1
On how many
days
in the
last month
did
you have a headache?
2
On how many
days
in the
last three
months
did your headaches
make it hard to work, study or carry
out household work?
3
On how many
days
in the
last three
months
did your headaches spoil or
prevent your family, social or leisure
activities?
HART Index (Headache and Assessment of Response to Treatment)
Your medical treatment for your headaches may not be as good as it can be.
By completing this short questionnaire, you will help your doctor or nurse improve it.
Please answer these questions carefully
none 1-2 3-5 6-15 16-30
none 1-5 6-10 11-20 21+
none 1-5 6-10 11-20 21+
Analysis(these questions establish frequency of all headaches and of disabling headaches under current treatment; ticks towards the right suggest increasing need for treatment review)
All ticks in white area Headache control is good: no review needed.
One or more ticks in lightly-shaded area Better acute headache management is needed; review Qs 4-8 for guidance; prophylaxis may not be required.
One or more ticks in middle-shaded area Headache control is not good; review Qs 4-8 to optimise acute medication; consider ways of reducing frequency (trigger avoidance and prophylactic medication).
One or more ticks in darkly-shaded area Disabling headache, poorly treated; possibly chronic daily headache (acute medication should be avoided); review Qs 4-8 and consider ways of reducing frequency.
Lifting The Burden
The Global Campaign to Reduce the Burden
of Headache Worldwide
A partnership in action between the World Health Organization, World Headache Alliance, International Headache Society and European Headache Federation
does one dose get rid of your headache
and keep it away?
6
Are you able to take your headache
medication without being bothered
by side effects?
7
Do you feel in control of your headaches?
8
What have you been told is your
headache diagnosis?
Do you feel you understand it?
Analysis(these questions suggest how current management might be improved)
Q4: Response should accord with Q1. When Advise patient about the risk and dangers of medication medication days are >10, there is risk of overuse. Consider ways to reduce frequency (trigger avoidance medication-overuse headache. and prophylactic medication).
Q5: Ticks towards the right increasingly Consider treating earlier, changing medication, dose or route of suggest poor efficacy administration, or using combination therapy, according to local
guidelines.
Q6: Ticks towards the right increasingly Consider changing medication or dose according to local suggest poor tolerability. guidelines.
Q7: This question relates to self-efficacy When the response is in the shaded area, look for the reason(s) in and to satisfaction. responses to Qs 1-6. If it is not evident, consider co-morbidities. The response should be concordant with When the response is not concordant, consider cognitive previous responses. interventions and expectation management.
Q8: This question relates to education. Always hand out the appropriate information leaflet. When the diagnosis is wrongly stated, or the answer “no” is given, further explanation may be necessary.
always often sometimes rarely never
always often sometimes rarely never
always often sometimes rarely never
yes no
please write your diagnosis here:
Introduction
Headache management is facilitated if the patient understands his or her headache disorder and the treatment being proposed for it. Compliance is improved and a better outcome is likely. Explanation takes time, which is often not available, but it should not be omit-ted.
A writing group* ofLifting The Burdenis developing a series of Patient Information Leaflets to be handed to patients at time of diagno-sis. These include leaflets on each of the four important headache disorders in primary care (migraine, tension-type headache, cluster headache and medication-overuse headache). A fifth leaflet explains some of the relation-ships between female hormones and headache, which commonly raise questions from patients. All of these are published in the following pages. The writing group includes an interna-tional review panel of headache spe-cialists, primary care physicians and patient representatives whose task is to ensure cross-cultural relevance in these leaflets.
*Lifting The Burden Writing and review group for Patient Information Leaflets:
E.A. MacGregor (lead writer) (UK), E.G.M. Couturier (Netherlands), E. Eggleston (Australia), M. Fontebasso (UK), L. Gardella (Argentina), R. Jensen (Denmark), Z. Katsarawa (Georgia/Germany), R. Kamoga (Uganda); H. Kettinen (Finland), D. Kernick (UK), MJA Láinez (Spain), P. Martelletti (Italy), P. Murphy (Eire), E. Ruiz de la Torre (Spain), E. O’Sullivan (Eire), J.M. Pereira Monteiro (Portugal), S. Qureshi (Saudi Arabia), K. Ravishankar (India), F. Sakai (Japan), N. Sharma (India), F. Sheftell (USA), T.J. Steiner (UK), L.J. Stovner (Norway), D. Valade (France), S.Y. Yu (PR China).
Information for Patients
T.J. Steiner
T.J. Steiner
Chairman: Global Campaign
What is migraine?
"When I get migraine it makes me very ill and really puts me out of action for the entire day or more. I can feel one coming on and then the full blown migraine emerges and I feel wretched and need to go to bed. As it progresses, I feel sick and eventually I am sick and then, finally, the pain begins to lessen. The next day I’m left with a vague pain and feel absolutely exhausted but otherwise okay."
Migraine is a medical disorder. It takes place in attacks, once or twice a year in some people but up to several times a month in others. The main feature of these attacks is headache, which may be severe. Other common features are feeling sick (nauseated) or being sick (vomiting) and finding light and noise uncomfortable.
If you feel nauseated when you have a headache, or light and noise bother you, or if your headache makes it difficult to carry out your usual daily activities, it is quite likely that it is migraine.
What causes migraine?
Migraine comes from the brain. It is a disorder of the parts of the brain that process pain and other sensations. You probably inherited it from one or other parent or from a grandparent. Who gets migraine?
About one in seven adults have migraine, so it is very com-mon. Women are three times more likely to be affected than men. It often starts in childhood or adolescence. In girls in particular it may start at puberty. Because of inheritance, migraine runs in families.
What are the different types of migraine?
The commonest is migraine without aura(aura is described later). About three-quarters of people with migraine have only this type; one in 10 have migraine with aura, and twice this many have both types from time to time. Much less common are attacks of aura alone, with no headache. This type of migraine tends to develop in older people. There are other types of migraine, but these are rare.
What are the symptoms of migraine?
Symptoms are present during the attack, which has four stages, although not all of these always happen. Between attacks, most people with migraine are completely well. The premonitoryphase comes before any other symptoms of the attack. Only half of people with migraine are aware of this phase. If you are one of these, you may feel irritable, depressed or tired for hours or even one or two days before the headache begins. However, some people find they are unusually ener-getic during this time. Some have food cravings. Others “just know” that a migraine attack is about to start.
The aura, when it happens, is almost always the next phase. Only a third of people with migraine ever have aura, and it may not be part of every attack even for them. Aura is a sig-nal from the brain, which is being temporarily (but not seri-ously) affected by the migraine process. It lasts, usually, for 10 to 30 minutes, but can be longer. It mostly affects vision. You may notice blank patches, bright or flashing lights or coloured zigzag lines spreading in front of your eyes, usu-ally to one side. Less common are sensory symptoms – pins-and-needles or numbness – which generally start in the fingers of one hand, and spread up the arm to affect that side of the face or tongue. When these happen, there are
